Please ensure Javascript is enabled for purposes of website accessibility

Orkambi a 2016 Blockbuster? Vertex Pharmaceuticals Incorporated Thinks So

By Brian Orelli, PhD - Apr 28, 2016 at 5:20PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Management sees Orkambi sales on track for $1 billion this year.

Vertex Pharmaceuticals (VRTX 0.05%) released earnings Wednesday, offering investors a look at how the launch of Orkambi is going and an update on its older medication, Kalydeco.

Vertex Pharmaceuticals results: The raw numbers

 

Q1 2016 Actuals

Q1 2015 Actuals

Growth (YOY)

Revenue

$398 million

$139 million

187%

(Loss) From Operations

($14 million)

($172 million)

N/A

(Loss) Per Share

($0.17)

($0.83)

N/A

What happened with Vertex Pharmaceuticals this quarter?

  • Orkambi pills. Image source: Vertex Pharmaceuticals.

    Sales of Kalydeco, Vertex's first cystic fibrosis drug, increased 31% year over year to $171 million, boosted by an increase in the number of patients eligible to take the drug.
  • Orkambi, which launched in July, produced sales of $223 million, only a slight increase over the fourth quarter sales of $220 million due to discontinuations matching new patients starting the medication.
  • Vertex gained approval for Orkambi in Canada and Australia, adding approximately 2,500 potential patients.
  • The company submitted an application to the Food and Drug Administration to treat children ages 6 to 11 with Orkambi, which would add 2,400 potential patients. In Europe, Vertex has to wait for data from an ongoing trial before it can apply to market the drug for children ages 6 to 11.

What management had to say
Chairman and CEO Jeff Leiden stressed that the market opportunity remains strong: "Consider that today Orkambi and Kalydeco are approved for approximately 27,000 people worldwide, but we're only currently treating approximately one-third of these patients." Adding that, "In total, we believe there are approximately 44,000 people, an additional 17,000 people beyond those eligible today, who could benefit from one of these two medicines."

While Orkambi and Kalydeco are clearly the most important drugs in the short term, Vertex has drugs further back in the pipeline, with Leiden noting, "We are on track to obtain the first data from the ongoing Phase 3 program for VX-661 in early 2017 from the study in people with two copies of the F508del mutation."

Looking forward
For the first time, management gave guidance for sales of Orkambi, predicting sales of $1 billion to $1.1 billion for this year. The guidance is based on increasing the 65% of eligible patients in the U.S. who are currently taking the drug to a "vast majority" by the end of the year. To hit the patient goal, Vertex needs the discontinuation rate to stay steady, with around 15% of patients stopping therapy in the first three months and 20% to 30% overall discontinuation rates.

Based on an increase in patients Kalydeco is approved for as well as a reduction in patients in clinical trials that would get the drug for free, management increased guidance for Kalydeco revenue for the year to between $685 million and $705 million, from a previous range of $670 million to $690 million.

Management didn't give earnings guidance, but Vertex only burned through about $10 million of its cash in the first quarter -- a rounding error on the company's nest egg of just over $1 billion. With increasing sales expected, GAAP profitability shouldn't be too far off.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Vertex Pharmaceuticals Incorporated Stock Quote
Vertex Pharmaceuticals Incorporated
VRTX
$268.48 (0.05%) $0.13

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
334%
 
S&P 500 Returns
117%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/24/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.